Saudi Arabia: – Lilly – Saudi Arabia, has announced the appointment of Dr. Mona Obaid to the role of Medical Director as of November 1st, 2020.
Dr. Obaid is the first Saudi female to hold such a Senior Leadership position across the Pharmaceutical industry in the Kingdom.
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. Founded more than a century ago, Lilly remains true to that mission, developing high-quality medicines that meet real-world needs and improve lives globally, including in the Kingdom.
Lilly has been serving patients for 40 years in the Kingdom, and in 2019 it became one of the first international pharmaceutical companies to establish a legal entity in the country. Lilly has always pushed the boundaries of science to make conditions that are incurable today, treatable tomorrow. Our portfolio of life changing medicines within the Kingdom spans across Diabetes, Immunology, Pain, Men’s Health, Oncology, and Osteoporosis.
Dr. Obaid’s appointment as Medical Director is Lilly Saudi Arabia’s latest addition to its Saudi affiliate Leadership team based in Riyadh. Dr. Obaid was the Director of Movement Disorders Program at the King Fahad Medical City until recently. She is a certified subspecialty consultant physician who holds a Medical Degree (MBBS) from King Saud University, and is board certified from the Saudi Internal Medicine Board (SIMB), Royal College Of Physicians of London (MRCP), and Canadian Board of Adult Neurology (FRCPC). She has completed two Fellowships; a Fellowship in Movement Disorders from University of Alberta, Canada, and Deep Brain Stimulation from University of Joseph Fourier, France and brings with her in her new role a wealth of experience and expertise of the healthcare industry within the Kingdom over her 15 year career where she held various Senior Leadership positions.
Besides being an expert in her field, Dr. Obaid is a mother of 3 and takes much interest in Arabic literature and is an enthusiastic traveler and holds a passion to learn about different cultures, history and enjoys visiting museums.
Within Lilly Saudi Arabia, Dr. Obaid will be specifically responsible for bringing forward Lilly’s pipeline of innovative medicines. Dr. Obaid commented: “It is a privilege to join such a forward-looking company that seeks to provide the best healthcare outcomes for Saudis and patients around the world. I look forward to using my experience to help drive this progress further, and to encourage more Saudi women to join Lilly Saudi Arabia”.
With this new addition, Lilly Saudi Arabia’s leadership team now consists of 25% females, a progress in line with the company’s commitment to a diverse and inclusive environment. Globally, Eli Lilly was named third in Diversity Inc’s 2020 list of Top 50 Companies for Diversity. While at Lilly we are proud of this achievement, we remain committed to advancing our diversity and inclusion journey further so that every single employee can bring their full authentic self to the workplace.
In Saudi Arabia, Lilly’s workforce consists of 75% millennials, and is made up predominately by Saudi nationals while rapidly reaching gender parity.
“We are delighted to have such a recognized talent as Dr. Mona joining us at a senior level” - Dimitri Livadas, Lilly’s Managing Director said. “In addition to her expertise, her appointment underlines Lilly Saudi Arabia’s determination to ensure that Diversity and Inclusion remain a cornerstone and focus of the company. Lilly is committed to attracting, developing, and retaining more local talents to represent best, the Saudi population whom we serve. That, in turn, allows us to better cater to their needs. In short, Saudi talents are essential for the future of the healthcare industry in the Kingdom”.
-Ends-
© Press Release 2020
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
